Poly-GA triggers TDP-43 pathology by inhibiting the proteasome and nucleocytoplasmic import in C9orf72 ALS/FTD
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
München, Ludwig-Maximilians-Universität, Dissertation, 2021
- Schlagwort
-
Pathology
- Ereignis
-
Veröffentlichung
- (wo)
-
München
- (wer)
-
Universitätsbibliothek der Ludwig-Maximilians-Universität
- (wann)
-
2021
- Urheber
- Beteiligte Personen und Organisationen
-
Edbauer, Dieter
- DOI
-
10.5282/edoc.28991
- URN
-
urn:nbn:de:bvb:19-289917
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Khosravi, Bahram
- Edbauer, Dieter
- Universitätsbibliothek der Ludwig-Maximilians-Universität
Entstanden
- 2021
Ähnliche Objekte (12)
TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD
SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution
A familial FTD associated with C9orf72 repeat expansion and dysplastic gangliocytoma
Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
Nuclear lamina invaginations are not a pathological feature of C9orf72 ALS/FTD
A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD
Targeting RNA G‐quadruplexes as new treatment strategy for C9orf72 ALS/FTD
Aktive und passive anti-GA Immuntherapie für C9orf72 ALS/FTD im Mausmodell
RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD
Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies
Disulfide cross-linked multimers of TDP-43 and spinal motoneuron loss in a TDP-43A315T ALS/FTD mouse model
TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD
SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution
A familial FTD associated with C9orf72 repeat expansion and dysplastic gangliocytoma
Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
Nuclear lamina invaginations are not a pathological feature of C9orf72 ALS/FTD
A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD
Targeting RNA G‐quadruplexes as new treatment strategy for C9orf72 ALS/FTD
Aktive und passive anti-GA Immuntherapie für C9orf72 ALS/FTD im Mausmodell
RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD
Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies
Disulfide cross-linked multimers of TDP-43 and spinal motoneuron loss in a TDP-43A315T ALS/FTD mouse model
TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD
SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution
A familial FTD associated with C9orf72 repeat expansion and dysplastic gangliocytoma
Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit
Nuclear lamina invaginations are not a pathological feature of C9orf72 ALS/FTD
A C9ORF72 BAC mouse model recapitulates key epigenetic perturbations of ALS/FTD
Targeting RNA G‐quadruplexes as new treatment strategy for C9orf72 ALS/FTD
Aktive und passive anti-GA Immuntherapie für C9orf72 ALS/FTD im Mausmodell
RNA dependent suppression of C9orf72 ALS/FTD associated neurodegeneration by Matrin-3
Divergence, Convergence, and Therapeutic Implications: A Cell Biology Perspective of C9ORF72-ALS/FTD
Specific biomarkers for C9orf72 FTD/ALS could expedite the journey towards effective therapies